The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis Oncology’s Rubraca, have revolutionized the therapeutic landscape of platinum-sensitive ovarian cancer, where platinum-based regimens used to be the standard of care. Although substantial improvements have been made with the FDA’s 2019 approval of Lynparza for first-line maintenance therapy in advanced ovarian cancer, opportunity exists to develop more effective therapies for platinum-sensitive disease, while optimal sequencing of these therapies remains an unmet need.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals in surveyed medical oncologists’ prescribing decisions? What are the hidden opportunities that developers could leverage?
  • How do current therapies, such as the PARP inhibitors, perform on key clinical attributes for this patient population?
  • What are the greatest areas of unmet need and most attractive opportunities for platinum-sensitive ovarian cancer?
  • What trade-offs are surveyed oncologists willing to make across key drug attributes and price when considering hypothetical target product profiles?

PRODUCT DESCRIPTION

Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 62 U.S. and 30 European medical oncologists fielded in June 2020

Key companies:  AstraZeneca, GSK, Clovis Oncology

Key drugs: Lynparza, Zejula, Rubraca

Table of contents

  • Ovarian Cancer - Unmet Need - Detailed, Expanded Analysis (US/EU)

Author(s): Laura Vinuesa, DVM, MSc

Laura Vinuesa, DVM, M.Sc., is a Senior Business Insights Analyst in the Oncology Division at Decision Resources Group, with expertise in thyroid carcinoma and bladder cancer. Previously, Dr. Vinuesa was an EU Market Access Analyst in the Global Market Access Insights Team at Decision Resources Group. She has expertise in market access, pricing and reimbursement, health technology assessment, and health policy.

Prior to joining Decision Resources, she worked as Market Access & Institutional Relations Analyst at Pfizer in Spain, providing support for the successful market launch of drugs for different areas: cardiovascular, oncology, mental disorder and rare disease. She is a Doctor of Veterinary Medicine from the Complutense University of Madrid, and holds a M.Sc. in Clinical Research and Pharmaceutical Medicine from EPHOS - School of PharmaStudies.

lvinuesa@TeamDRG.com


Related Reports

Ovarian Cancer - Landscape & Forecast - Disease Landscape & Forecast

The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but now, with the introduction of Roche/Genentech/Chugai’s Avastin and three PA...

View Details

Ovarian Cancer - Epidemiology - Mature Markets

DRG Epidemiology's coverage of ovarian cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We...

View Details